Skip to main content
Qingdao Haier Biomedical Co.,Ltd logo

Qingdao Haier Biomedical Co.,Ltd — Investor Relations & Filings

Ticker · 688139 ISIN · CNE100003P25 LEI · 65560007PZ5ME4672K78 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 750 across all filing types
Latest filing 2026-05-22 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688139

About Qingdao Haier Biomedical Co.,Ltd

https://www.haiermedical.com/

Qingdao Haier Biomedical Co.,Ltd. focuses on the development and distribution of low-temperature storage solutions and digital infrastructure for life science and medical research. The company’s portfolio includes ultra-low temperature freezers, medical refrigerators, biosafety cabinets, and laboratory equipment. It specializes in integrating Internet of Things (IoT) technology to provide end-to-end solutions for biological sample banking, blood management, and vaccination safety. These systems facilitate real-time monitoring and automated tracking of sensitive biological materials. The company serves a diverse range of institutions, including hospitals, research centers, and pharmaceutical enterprises, aiming to optimize biosafety and operational efficiency through advanced cold chain technology and integrated digital management platforms.

Recent filings

Filing Released Lang Actions
海尔生物关于2026年员工持股计划完成非交易过户的公告
Transaction in Own Shares Classification · 90% confidence The document is an official disclosure by Qingdao Haier Biomedical Co., Ltd. announcing the completion of a non-trading transfer of shares from the company’s repurchase account to its 2026 Employee Stock Ownership Plan. This describes the company’s transaction in its own shares (transferring treasury shares to employees), fitting the “Transaction in Own Shares (POS)” category.
2026-05-22 Chinese
海尔生物未来三年（2026-2028）股东分红回报规划
Regulatory Filings Classification · 95% confidence The document is titled as a "Future Three-Year (2026-2028) Shareholder Dividend Return Plan" issued by the board of Qingdao Haier Biomedical Co., Ltd. It outlines the company's dividend policy, principles, planning, decision-making procedures, and adjustment mechanisms for shareholder returns over the next three years. The content focuses on dividend distribution methods, cash dividend conditions, stock dividends, and governance around dividend decisions. There are no financial statements, audit reports, or earnings data presented. The document is a policy or planning announcement related to dividends rather than an actual dividend payment notice or financial report. It is not a Notice of Dividend Amount (DIV) because it does not announce specific dividend amounts or payment dates for a particular period. Instead, it is a forward-looking dividend policy plan. Given the nature of the document as a formal policy announcement by the board regarding shareholder returns and dividend planning, it best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-03-27 Chinese
海尔生物2026年员工持股计划（草案）摘要的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's 2026 Employee Stock Ownership Plan (员工持股计划). It includes comprehensive information about the plan's purpose, principles, participants, funding sources, stock sources, pricing, duration, lock-up periods, performance assessments, management structure, rights and obligations, and conditions for changes or termination. The document is lengthy (15,000 characters) and contains substantive details about the stock ownership plan, including financial and governance aspects related to employee stock ownership. It is not a simple announcement of a report publication, nor is it a certification or a brief summary. It is not an annual or quarterly financial report, nor an earnings release. It is not a proxy solicitation or voting results announcement. The content focuses on the employee stock ownership plan, which is a form of capital/financing update related to company fundraising and capital structure changes through employee stock participation. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-27 Chinese
海尔生物2025年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2025年度董事会审计委员会履职情况报告" which translates to the "2025 Annual Board Audit Committee Performance Report." It details the audit committee's activities, including supervision of external auditors, review of financial reports, internal audit guidance, related party transactions, and fundraising management. The document includes detailed descriptions of audit committee meetings and their agenda items, such as reviewing quarterly and semi-annual financial reports and audit evaluations. The content focuses on audit committee oversight and audit-related governance rather than presenting full financial statements or comprehensive annual financial performance. The document length is 2897 characters, which is relatively short and more consistent with a committee report rather than a full Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification but a substantive report on audit committee activities. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related audit committee oversight information, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence.
2026-03-27 Chinese
海尔生物2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Ernst & Young Hua Ming for the fiscal year 2025. It details the qualifications, audit process, quality management, and overall assessment of the audit firm in relation to the company's 2025 financial report audit and internal control audit. It mentions the issuance of an unqualified audit opinion and compliance with relevant auditing standards. The document is a standalone audit evaluation report related to the audit of the annual financial statements, not the annual report itself. It does not contain the full financial statements or comprehensive company activity details typical of an Annual Report (10-K). The document is also not a brief announcement or certification but a detailed audit performance evaluation. Therefore, it fits the category of an Audit Report / Information (AR). The document length is 4404 characters, which is sufficient for a detailed report but not a brief announcement. Hence, the classification is AR with high confidence.
2026-03-27 Chinese
青岛海尔生物医疗股份有限公司信息披露事务管理制度（2026年3月）
Governance Information Classification · 95% confidence The document is a detailed information disclosure management system of Qingdao Haier Biomedical Co., Ltd., outlining principles, requirements, and procedures for information disclosure. It references regulatory frameworks such as the Securities Law of China, Shanghai Stock Exchange rules, and China Securities Regulatory Commission requirements. The content includes detailed rules on periodic reports (annual, semi-annual, quarterly), interim reports, audit reports, disclosure of major events, risk factors, and other regulatory compliance matters. It is a governance and compliance document rather than a financial report or announcement. It does not contain actual financial data or results but rather the internal rules and procedures for disclosure. Therefore, it fits best under Governance Information (CGR).
2026-03-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.